NEO-PV-01 + Nivolumab in Advanced Cancers

Phase 1, open-label, single-arm trial of NeoVax in melanoma, non-small cell lung cancer (NSCLC) and bladder cancer, sponsored by BioNTech SE. Primary endpoint: Rate of adverse events including SAEs and AEs leading to treatment discontinuation, changes in safety laboratory evaluations, physical examination findings, vital signs findings, and changes in ECOG… Started Oct 2016; status: completed.